Mono Pharmacare
Key Fundamentals
SMEPharmaceuticals & BiotechnologyHealthcarePrice-based figures as of · TTM
- ROCE
- 5.10%
- Debt to Equity
- 1.75
- EPS (TTM)
- —
- Book Value
- ₹17.86
- Market Cap
- —
- P/E (TTM)
- —
- P/B
- 0.54
- ROE
- 2.33%
- Dividend Yield
- 0.00%
- EBITDA
- ₹4.50 Cr
- 52W High
- ₹22.05
- 52W Low
- ₹7.50
- Day Range
- ₹9.65 – ₹9.65
- Volume
- 2,000
Peer Comparison
Healthcare › Pharmaceuticals
| ₹1,773.40 | 38.81 | ₹4,29,049 Cr | 4.77 | 0.90% | 16.00% | 20.50% | ₹61,631 Cr | ₹10,987 Cr | |
| ₹10,037.50 | 91.10 | ₹2,65,269 Cr | 15.90 | 0.30% | 16.50% | 22.00% | ₹11,230 Cr | ₹2,925 Cr | |
| ₹4,738.50 | 78.61 | ₹1,77,061 Cr | 9.81 | 0.82% | 27.40% | 15.20% | ₹17,400 Cr | ₹2,099 Cr | |
| ₹1,188.10 | 26.44 | ₹1,25,446 Cr | 4.37 | 0.08% | 21.20% | 21.10% | ₹28,592 Cr | ₹4,593 Cr | |
| ₹2,323.80 | 114.81 | ₹1,25,228 Cr | 20.72 | 0.04% | 18.30% | 17.80% | ₹7,270 Cr | ₹1,090 Cr | |
| ₹1,374.00 | 35.59 | ₹1,14,543 Cr | 2.96 | 0.58% | 11.20% | 13.00% | ₹33,228 Cr | ₹3,184 Cr | |
| ₹1,402.00 | 33.59 | ₹1,12,454 Cr | 3.20 | 0.93% | 11.60% | 15.50% | ₹28,324 Cr | ₹3,356 Cr | |
| Mono Pharmacare (this company) | ₹9.65 | — | ₹16 Cr | 0.54 | 0.00% | 2.33% | 5.10% | — | — |
| Median 8 companies | ₹1,587.70 | 38.81 | ₹1,25,337 Cr | 4.57 | 0.44% | 16.25% | 16.65% | ₹28,324 Cr | ₹3,184 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
Data confidence 81/100
Category scores
- Quality
- 38
- Weak
- Returns, margins, earnings quality 22% weight
- Valuation
- 75
- Strong
- Cheap vs sector & own history 24% weight
- Growth
- 34
- Poor
- Sales & profit trajectory 9% weight
- Financial Health
- 19
- Poor
- Solvency, leverage, coverage 9% weight
- Momentum
- 16
- Poor
- Trend strength, vol-adjusted 12% weight
- Ownership
- 50
- Average
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
1- Stock is trading at 0.48 times its book value
Weaknesses
5- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- Company has a low return on equity of 7.64% over last 3 years.
- Company might be capitalizing the interest cost
- Company has high debtors of 165 days.
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Bullish | 6 | 4 | 9 |
| Oscillators | Bullish | 2 | 4 | 3 |
| Moving Averages | Strong Bullish | 4 | 0 | 6 |
Oscillators
Bullish
Overall
Bullish
Moving Averages
Strong Bullish
Key readings
- RSI (14)
- 59.58
- Neutral
- MACD (12,26,9)
- 0.06
- Bullish
- SMA (50)
- 9.01
- Bullish
- SMA (200)
- 14.13
- Bearish
As of
Growth Rate
From the financial statements below. 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025.
Revenue
| 3Y | Irregular period |
|---|---|
| 1Y | −1.19% |
Net profit
| 3Y | Irregular period |
|---|---|
| 1Y | −66.67% |
Operating cash flow
| 3Y | Irregular period |
|---|---|
| 1Y | Turned positive |
Operating margin· change in pp
| 3Y | Irregular period |
|---|---|
| 1Y | −1.75 pp |
Trailing twelve months: Results are not reported for each of the last eight quarters, so there is no trailing-twelve-month figure.
Revenue by year
| Mar 2024 | ₹122 Cr |
|---|---|
| Mar 2025 | ₹168 Cr |
| Mar 2026 | ₹166 Cr |
Net profit by year
| Mar 2024 | ₹2.00 Cr |
|---|---|
| Mar 2025 | ₹3.00 Cr |
| Mar 2026 | ₹1.00 Cr |
Half-yearly Results
₹ Cr| Particulars | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Sales | 35 | 67 | 56 | 87 | 81 | 66 | 99 |
| Expenses | 33 | 63 | 53 | 82 | 78 | 65 | 97 |
| Operating Profit | 2 | 4 | 2 | 5 | 3 | 2 | 2 |
| OPM % | 6% | 6% | 4.4% | 5% | 3.6% | 2.7% | 2.2% |
| Other Income | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Interest | 1 | 2 | 2 | 2 | 2 | 2 | 2 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PBT | 1 | 2 | 1 | 3 | 1 | 0 | 0 |
| Tax % | 39% | 20% | 33% | 27% | 37% | 83% | 29% |
| Net Profit | 1 | 2 | 1 | 2 | 1 | 0 | 0 |
| EPS (₹) | 0.52 | 1.06 | 0.33 | 1.3 | 0.46 | 0.01 | 0.19 |
Profit & Loss
₹ Cr| Particulars | Mar 2023 6m | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Sales | 33 | 122 | 168 | 166 |
| Expenses | 31 | 116 | 161 | 161 |
| Operating Profit | 2 | 6 | 8 | 5 |
| OPM % | 7% | 5% | 4.5% | 2.7% |
| Other Income | 0 | 0 | 1 | 0 |
| Interest | 1 | 3 | 4 | 3 |
| Depreciation | 0 | 0 | 0 | 0 |
| PBT | 1 | 3 | 4 | 1 |
| Tax % | 29% | 24% | 30% | 32% |
| Net Profit | 1 | 2 | 3 | 1 |
| EPS (₹) | 0.76 | 1.38 | 1.75 | 0.41 |
| Div. Payout % | 0% | 0% | 0% | 0% |
Balance Sheet
₹ Cr| Particulars | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 12 | 18 | 18 | 18 |
| Reserves | 1 | 10 | 14 | 14 |
| Borrowings | 40 | 41 | 54 | 56 |
| Other Liabilities | 9 | 12 | 25 | 34 |
| Total Liabilities | 63 | 81 | 110 | 122 |
| Fixed Assets | 1 | 1 | 1 | 1 |
| CWIP | 0 | 0 | 0 | 0 |
| Investments | 1 | 0 | 0 | 0 |
| Other Assets | 61 | 80 | 109 | 121 |
| Total Assets | 63 | 81 | 110 | 122 |
Cash Flow
₹ Cr| Particulars | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Operating | −40 | −9 | −4 | 3 |
| Investing | −1 | 0 | 0 | 0 |
| Financing | 41 | 8 | 5 | −2 |
| Net Cash Flow | 0 | 0 | 0 | 0 |
| Free Cash Flow | −40 | −9 | −5 | 3 |
| CFO/OP | −1,765 | −127 | −38 | 68 |
Ratios
| Particulars | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Debtor Days | 241 | 94 | 91 | 165 |
| Inventory Days | 408 | 139 | 133 | 99 |
| Days Payable | 87 | 32 | 45 | 68 |
| Cash Conversion Cycle | 563 | 202 | 179 | 196 |
| Working Capital Days | 299 | 131 | 120 | 126 |
| ROCE % | — | 10% | 11% | 5% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Mono Pharmacare insights
55 extracted metrics across FY22–FY26.
Documents
- 2 Oct 2026
- 30 Sep 2026
- 28 Sep 2026
- 17 Sep 2026
- 9 Sep 2026
Frequently Asked Questions about Mono Pharmacare
What does Mono Pharmacare Ltd do?
Where is Mono Pharmacare Ltd (MONOPHARMA) listed?
Which sector does Mono Pharmacare Ltd belong to?
What is the 52-week high and low of Mono Pharmacare Ltd?
What is the Return on Equity (ROE) of Mono Pharmacare Ltd?
Company Information
Incorporated in 1994, Mono Pharmacare Ltd is in the business of distribution of Pharmaceutical items
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/MONOPHARMA.md for Mono Pharmacare Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.